222 related articles for article (PubMed ID: 24886133)
1. Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndrome.
O'Brien TJ; Harralson AF; Tran T; Gindoff I; Orkunoglu-Suer FE; Frankfurter D; Gindoff P
Reprod Biol Endocrinol; 2014 May; 12():36. PubMed ID: 24886133
[TBL] [Abstract][Full Text] [Related]
2. Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation.
O'Brien TJ; Kalmin MM; Harralson AF; Clark AM; Gindoff I; Simmens SJ; Frankfurter D; Gindoff P
Reprod Biol Endocrinol; 2013 Jul; 11():71. PubMed ID: 23883350
[TBL] [Abstract][Full Text] [Related]
3. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
4. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of ovarian hyperstimulation syndrome following controlled ovarian hyperstimulation in patients with vascular endothelial growth factor +405 cc genotype.
Hanevik HI; Hilmarsen HT; Skjelbred CF; Tanbo T; Kahn JA
Gynecol Endocrinol; 2012 Nov; 28(11):845-9. PubMed ID: 22587628
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of VEGF and VEGF receptors are associated with the occurrence of ovarian hyperstimulation syndrome (OHSS)-a retrospective case-control study.
Nouri K; Haslinger P; Szabo L; Sator M; Schreiber M; Schneeberger C; Pietrowski D
J Ovarian Res; 2014; 7():54. PubMed ID: 24851136
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
[TBL] [Abstract][Full Text] [Related]
8. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
9. Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women.
Achrekar SK; Modi DN; Desai SK; Mangoli VS; Mangoli RV; Mahale SD
Fertil Steril; 2009 Feb; 91(2):432-9. PubMed ID: 18321487
[TBL] [Abstract][Full Text] [Related]
10. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
[TBL] [Abstract][Full Text] [Related]
11. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles.
Sousa M; Cunha M; Teixeira da Silva J; Oliveira C; Silva J; Viana P; Barros A
Reprod Biol Endocrinol; 2015 Jun; 13():66. PubMed ID: 26100393
[TBL] [Abstract][Full Text] [Related]
12. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
[TBL] [Abstract][Full Text] [Related]
13. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
14. GnRH Agonist Triggering Modulates PEDF to VEGF Ratio Inversely to hCG in Granulosa Cells.
Miller I; Chuderland D; Ron-El R; Shalgi R; Ben-Ami I
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1428-36. PubMed ID: 26308290
[TBL] [Abstract][Full Text] [Related]
15. Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS).
Morón FJ; de Castro F; Royo JL; Montoro L; Mira E; Sáez ME; Real LM; González A; Mañes S; Ruiz A
Pharmacogenet Genomics; 2006 Jul; 16(7):485-95. PubMed ID: 16788381
[TBL] [Abstract][Full Text] [Related]
16. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
[TBL] [Abstract][Full Text] [Related]
17. Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.
Kalampokas T; Creatsas G; Kalampokas E
Gynecol Endocrinol; 2013 Feb; 29(2):98-100. PubMed ID: 23110560
[TBL] [Abstract][Full Text] [Related]
18. The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model.
Wei LH; Chou CH; Chen MW; Rose-John S; Kuo ML; Chen SU; Yang YS
J Clin Endocrinol Metab; 2013 Mar; 98(3):E472-84. PubMed ID: 23348396
[TBL] [Abstract][Full Text] [Related]
19. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor.
Wang TH; Horng SG; Chang CL; Wu HM; Tsai YJ; Wang HS; Soong YK
J Clin Endocrinol Metab; 2002 Jul; 87(7):3300-8. PubMed ID: 12107240
[TBL] [Abstract][Full Text] [Related]
20. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles.
Nargund G; Hutchison L; Scaramuzzi R; Campbell S
Reprod Biomed Online; 2007 Jun; 14(6):682-5. PubMed ID: 17579978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
